India’s first coronavirus vaccine, COVAXIN, which has been developed by Bharat Biotech, has received approval from the DCGI to conduct Phase I and II human clinical trials. These trials are scheduled to start across the country in July.
COVAXIN, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV), gets nod from Drugs Controller General of India (DCGI) for phase I and II human clinical trials.